Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 10/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 6/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SQLE | Q14534 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332449 | 0.85 | MAOA (0.47) | TDP1BACE1IDO1MAOAMAOB | |
| SCHEMBL20298754 | 0.84 | LCK (0.44) | TP53BACE1IDO1MAOAMAOB | |
| SCHEMBL8348643 | 0.81 | ALDH1A1 (0.38) | TP53BACE1ALDH1A1TSHR | |
| SCHEMBL8024700 | 0.80 | TP53 (0.36) | TP53TDP1MAOAMAOBFAAH | |
| Alcohol SCHEMBL9337072 | 0.80 | MAOA (0.43) | TDP1BACE1MAOAMAOBALDH1A1 | |
| SCHEMBL9626381 | 0.80 | BACE1 (0.35) | BACE1IDO1MAOAMAOBALDH1A1 | |
| SCHEMBL16537338 | 0.80 | TDP1 (0.41) | TP53TDP1IDO1MAOAMAOB | |
| SCHEMBL16538035 | 0.80 | TDP1 (0.41) | TP53TDP1IDO1MAOAMAOB | |
| SCHEMBL27544251 | 0.80 | IDO1 (0.36) | BACE1IDO1AGXTCYP3A4 | |
| SCHEMBL8344755 | 0.79 | BACE1 (0.34) | BACE1IDO1MAOAMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102206313-B | Star polymer and process for production thereof | NIPPON SODA CO | 2013-06-05 | — | — | CN | disclosed |
| CN-101258184-B | Star polymer and process for producing the same | NIPPON SODA CO | 2012-05-23 | — | — | CN | disclosed |
| CN-102206313-A | Star polymer and process for production thereof | NIPPON SODA CO | 2011-10-05 | — | — | CN | disclosed |
| CN-101258184-A | Star polymer and process for producing the same | NIPPON SODA CO (JP) | 2008-09-03 | — | — | CN | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5932675-A | Free-radical chain transfer polymerization process | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-08-03 | — | — | US | disclosed |
| US-5874511-A | CHAIN TRANSFER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | TP53 4701/4885TDP1 353/4885BACE1 4259/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | TP53 4756/4885TDP1 482/4885BACE1 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.